智通财经APP讯,长风药业(02652)发布公告,根据上海证券交易所及深圳证券交易所发布的港股通标的证券名单调整公告,本公司H股已正式获纳入沪港通及深港通下的港股通标的证券名单,有关调整自2026年3月9日起生效。
自生效日起,符合港股通准入条件的中国内地投资者将可透过沪港通及深港通下的港股通机制,交易本公司于香港联合交易所有限公司上市的H股。
董事会预期,是次纳入将有助于扩大本公司的股东基础,提升本公司H股的交易流动性。
智通财经APP讯,长风药业(02652)发布公告,根据上海证券交易所及深圳证券交易所发布的港股通标的证券名单调整公告,本公司H股已正式获纳入沪港通及深港通下的港股通标的证券名单,有关调整自2026年3月9日起生效。
自生效日起,符合港股通准入条件的中国内地投资者将可透过沪港通及深港通下的港股通机制,交易本公司于香港联合交易所有限公司上市的H股。
董事会预期,是次纳入将有助于扩大本公司的股东基础,提升本公司H股的交易流动性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.